ITMI921601A0 - Uso di nor e omo-derivati di acidi biliari come promotori di assorbimento di farmaci - Google Patents

Uso di nor e omo-derivati di acidi biliari come promotori di assorbimento di farmaci

Info

Publication number
ITMI921601A0
ITMI921601A0 IT92MI1601A ITMI921601A ITMI921601A0 IT MI921601 A0 ITMI921601 A0 IT MI921601A0 IT 92MI1601 A IT92MI1601 A IT 92MI1601A IT MI921601 A ITMI921601 A IT MI921601A IT MI921601 A0 ITMI921601 A0 IT MI921601A0
Authority
IT
Italy
Prior art keywords
homo
promoters
derivatives
bile acids
drug absorption
Prior art date
Application number
IT92MI1601A
Other languages
English (en)
Inventor
Fabio Berlati
Giancarlo Ceschel
Celestino Ronchi
Aldo Roda
Enrico Roda
Original Assignee
Monteresearch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monteresearch filed Critical Monteresearch
Publication of ITMI921601A0 publication Critical patent/ITMI921601A0/it
Priority to ITMI921601A priority Critical patent/IT1255449B/it
Priority to JP6501998A priority patent/JPH07508013A/ja
Priority to EP93912975A priority patent/EP0652773B1/en
Priority to US08/360,833 priority patent/US5656277A/en
Priority to PCT/EP1993/001508 priority patent/WO1994000155A1/en
Priority to AT93912975T priority patent/ATE161731T1/de
Priority to ES93912975T priority patent/ES2114056T3/es
Priority to DE69316217T priority patent/DE69316217T2/de
Priority to DK93912975T priority patent/DK0652773T3/da
Publication of ITMI921601A1 publication Critical patent/ITMI921601A1/it
Application granted granted Critical
Publication of IT1255449B publication Critical patent/IT1255449B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ITMI921601A 1992-06-30 1992-06-30 Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci. IT1255449B (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ITMI921601A IT1255449B (it) 1992-06-30 1992-06-30 Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.
PCT/EP1993/001508 WO1994000155A1 (en) 1992-06-30 1993-06-15 The use of nor- and homo- bile acids derivatives as absorption enhancers for medicaments
EP93912975A EP0652773B1 (en) 1992-06-30 1993-06-15 The use of nor- and homo- bile acids derivatives as absorption enhancers for medicaments
US08/360,833 US5656277A (en) 1992-06-30 1993-06-15 Nor- and homo- bile acids derivatives as absorption enhancers for medicaments
JP6501998A JPH07508013A (ja) 1992-06-30 1993-06-15 医薬物用吸収促進剤としてのノルおよびホモ胆汁酸誘導体の使用
AT93912975T ATE161731T1 (de) 1992-06-30 1993-06-15 Anwendung von nor- und homo-gallensäurederivaten als absorptienförderer für arzneimittel
ES93912975T ES2114056T3 (es) 1992-06-30 1993-06-15 Uso de derivados nor y homo de acidos biliares como potenciadores de absorcion para medicamentos.
DE69316217T DE69316217T2 (de) 1992-06-30 1993-06-15 Anwendung von nor- und homo-gallensäurederivaten als absorptienförderer für arzneimittel
DK93912975T DK0652773T3 (da) 1992-06-30 1993-06-15 Anvendelse af nor- og homo-galdesyrederivater somabsorptionsfremmende bestanddele i lægemidler

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI921601A IT1255449B (it) 1992-06-30 1992-06-30 Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.

Publications (3)

Publication Number Publication Date
ITMI921601A0 true ITMI921601A0 (it) 1992-06-30
ITMI921601A1 ITMI921601A1 (it) 1993-12-30
IT1255449B IT1255449B (it) 1995-10-31

Family

ID=11363597

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI921601A IT1255449B (it) 1992-06-30 1992-06-30 Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.

Country Status (9)

Country Link
US (1) US5656277A (it)
EP (1) EP0652773B1 (it)
JP (1) JPH07508013A (it)
AT (1) ATE161731T1 (it)
DE (1) DE69316217T2 (it)
DK (1) DK0652773T3 (it)
ES (1) ES2114056T3 (it)
IT (1) IT1255449B (it)
WO (1) WO1994000155A1 (it)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0821970A1 (en) * 1996-08-02 1998-02-04 Edward Henri Charles Verhaeren Carrier composition for influencing the tight junction permeability
DE69834038D1 (de) 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
NZ511072A (en) 1998-10-05 2004-03-26 Penn State Res Found Method for enhancing receptor-mediated cellular internalization using a composition of an active agent and a viscous material and an enhancer
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6451286B1 (en) 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20030118547A1 (en) * 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
JP4452970B2 (ja) * 2002-03-27 2010-04-21 日本臓器製薬株式会社 ジクロフェナクナトリウム経口製剤
JP4584987B2 (ja) 2004-04-30 2010-11-24 アルニラム ファーマスーティカルズ インコーポレイテッド Ｃ５修飾ピリミジンを含むオリゴヌクレオチド
WO2006119803A1 (en) 2005-05-12 2006-11-16 Medizinische Universität Graz USE OF 24-nor-UDCA
SI2182954T1 (sl) * 2007-07-25 2019-04-30 Medizinische Universitat Graz Uporaba nor-žolčnih kislin pri zdravljenju arterioskleroze
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
AU2015343025A1 (en) 2014-11-06 2017-06-08 Enanta Pharmaceuticals, Inc. Bile acid analogs an FXR/TGR5 agonists and methods of use thereof
CA2968404A1 (en) * 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CA2975257A1 (en) 2015-02-11 2016-08-18 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10457703B2 (en) 2015-03-31 2019-10-29 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
MX2019006165A (es) 2016-11-29 2019-10-14 Enanta Pharm Inc Proceso para la preparacion de derivados del acido biliar de las sulfonilureas.
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
US10676500B2 (en) 2017-04-07 2020-06-09 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
GB201911821D0 (en) 2019-08-16 2019-10-02 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds for use in the treatment of liver disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
IT1212835B (it) * 1983-08-18 1989-11-30 Lehner Ag Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.

Also Published As

Publication number Publication date
EP0652773B1 (en) 1998-01-07
US5656277A (en) 1997-08-12
ITMI921601A1 (it) 1993-12-30
IT1255449B (it) 1995-10-31
ES2114056T3 (es) 1998-05-16
DK0652773T3 (da) 1998-09-07
JPH07508013A (ja) 1995-09-07
WO1994000155A1 (en) 1994-01-06
EP0652773A1 (en) 1995-05-17
DE69316217D1 (de) 1998-02-12
DE69316217T2 (de) 1998-08-20
ATE161731T1 (de) 1998-01-15

Similar Documents

Publication Publication Date Title
ITMI921601A0 (it) Uso di nor e omo-derivati di acidi biliari come promotori di assorbimento di farmaci
NO944535D0 (no) Salter av peptider med karboksy-avsluttede polyestere
NO924978D0 (no) Chinolon- og naftyridon-karboksylsyrederivater
MA23226A1 (fr) Derives optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-
KR960702768A (ko) 촉매 조성물 및 카복실산 에스테르의 수소화에서의 이들의 용도(catalyst compositions and the use thereof in the hydrogenation of carboxylic acid esters)
DE69328492D1 (de) Fettsäure-derivate und diese enthaltende pharmazeutische präparationen
ATE253582T1 (de) Prodrogs und analoga von camptothecin und deren verwendung als arzneimittel
IT8868117A0 (it) Solfonammidi di benzilidene canfora derivanti da amminoacidi e loro impiego in cosmesi particolarmente come filtri solari
DE69507006D1 (de) Ceramid-3-derivate von einfachungesättigten fettsäuren
ITMI921602A0 (it) Uso di acidi biliari come agenti antivirali
DE59404990D1 (de) Fettsäureester von Methylglucosid-Derivaten
DE69323200D1 (de) Diazonaphthochinonsulfonsäureester von hexahydroxybenzophenon als sensibilisatoren und positiv-photoresists auf deren basis
ITPD910163A0 (it) Nuovo uso di esteri di polisaccarici acidi
ITMI921767A0 (it) Derivato di acido biliare e suo uso in terapia
DE69413544D1 (de) Reduzierte absorption von fettsäuren
DE69312473D1 (de) Zerstäubungsvorrichtung von therapeutischen Substanzen
IT1228893B (it) Derivati tetrazol ammidici di acidi alchenil eterociclici e loroimpiego come sostanze antiallergiche
DE3483271D1 (de) Esterderivate von 7-(omega-oxyalkyl)-theophyllin und ihre pharmazeutische aktivitaet.
NO950731D0 (no) Optisk aktive karboksamidderivater
DE68910029D1 (de) Ester-Derivat von Phenylbicyclohexanol.
ITMI922534A0 (it) Uso di acidi aril-, eteroaril- e alchiltartronici come agenti terapeutici
DE69306694D1 (de) Kristalle von Hydroxyphenylpropionsäure-ester und ihre Herstellung
DE69313442D1 (de) Hydroxyderivate von cyclohexadien
DE69323981D1 (de) Verfahren zur Herstellung von optisch aktiven 4-Mercapto-2-pyrrolidionderivat und Zwischenprodukt dafür
NO930947D0 (no) Cykloalkyl- og heterocyklylsubstituerte imidazolylpropensyrederivate

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960627